Antibodies
21 January 2009
Seattle Genetics Receives Special Protocol Assessment for SGN-35 Pivotal Trial in Hodgkin Lymphoma20 January 2009
Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer19 January 2009
MorphoSys Provides Update on Pipeline Activities in 200914 January 2009
Merck KGaA: New Data Reinforce Consistent Efficacy Profile of Erbitux in First-Line mCRC Patients with KRAS Wild-Type Tumors12 January 2009
Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG5 January 2009
UCB receives Complete Response Letter from U.S. FDA for use of Cimzia(R) in rheumatoid arthritis patients5 January 2009
Genmab Announces Interim Results in Pivotal Study of Zalutumumab in Head and Neck Cancer5 January 2009
Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients23 December 2008
Phase II study shows trifunctional antibody Removab(R) (catumaxomab) well tolerated in treatment of gastric cancer19 December 2008
FDA Issues Complete Response Letter to Centocor fot Ustekinumab Biologis License Application18 December 2008
Genmab Sells Arzerra Co-Promotion Rights to GlaxoSmithKline18 December 2008
Phase III Study Showed Rituxan® Decreased The Progression Of Joint Damage In Patients With Early Rheumatoid Arthritis (RA)15 December 2008
Approval of STELARA(TM) in Canada Marks Advancement in Treatment of Moderate to Severe Plaque Psoriasis12 December 2008
Ablynx REports Positive Phase Ib Results for Its Anti-Thrombotic Nanobody(R) ALX-008111 December 2008
Crucell Announces Excellent Results for Influenza Antibody11 December 2008
Herceptin given prior to surgery improves the chance of survival without relapse for women with HER2-positive breast cancer10 December 2008
Seattle Genetics Announces Interim Safety Analysis Supports Continuation of Lintuzumab Phase IIb Clinical Trial10 December 2008
Active Biotech’s Cancer Project ANYARA: Combination with Established Tumor Therapies Promising10 December 2008
ABLYNX REACHES MILESTONE IN TNF-alpha NANOBODY(R) COLLABORATION AS WYETH PHARMACEUTICALS INITIATES PHASE I10 December 2008
XOMA Provides Clinical Plan Update On Diabetes Drug CandidateNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports